Single-eye gene therapy improves vision in both eyes of patients with inherited eye disorder

December 09, 2020

A gene therapy for an inherited eye disorder can ameliorate vision loss in both eyes despite only being injected into one, according to a phase 3 clinical trial involving 37 patients. The treated patients showed sustainable improvements in vision after 96 weeks, providing evidence the gene therapy could offer a safe and effective therapy for Leber hereditary optic neuropathy (LHON), an inherited blinding disease with few treatments. The study also yields clues about why the treatment unexpectedly seemed to work in both eyes, a finding that could guide future research into similar treatments. Gene therapies with viral vectors have been tested as interventions for an array of genetic disorders, including LHON. Although scientists are still refining gene therapy approaches, there has been substantial progress over the past decade, and some treatments have begun to enter the final phases of clinical testing. Patrick Yu-Wai-Man and colleagues treated 37 patients with vision loss due to LHON with a viral vector that corrects genetic defects in mitochondria, the energy producers of cells. Surprisingly, 78% of the patients showed improvements in vision in both eyes after 96 weeks with only mild side effects, even though the therapy was only injected into the right eye of each subject. The scientists explored this finding more in nonhuman primates and reported that DNA from the vectors could be found in both treated and untreated eyes. At the end of the study, the patients also reported improvements in independence, mental health, general vision, and other quality-of-life metrics. Yu-Wai-Man et al. caution their study lacked a true prospective control group, and recommend conducting further trials to pin down the mechanisms that enabled both eyes to improve.

American Association for the Advancement of Science

Related Gene Therapy Articles from Brightsurf:

Risk of AAV mobilization in gene therapy
New data highlight safety concerns for the replication of recombinant adeno-associated viral (rAAV) vectors commonly used in gene therapy.

Discovery challenges the foundations of gene therapy
An article published today in Science Translational Medicine by scientists from Children's Medical Research Institute has challenged one of the foundations of the gene therapy field and will help to improve strategies for treating serious genetic disorders of the liver.

Gene therapy: Novel targets come into view
Retinitis pigmentosa is the most prevalent form of congenital blindness.

Gene therapy targets inner retina to combat blindness
Batten disease is a group of fatal, inherited lysosomal storage disorders that predominantly affect children.

New Human Gene Therapy editorial: Concern following gene therapy adverse events
Response to the recent report of the deaths of two children receiving high doses of a gene therapy vector (AAV8) in a Phase I trial for X-linked myotubular myopathy (MTM).

Restoring vision by gene therapy
Latest scientific findings give hope for people with incurable retinal degeneration.

Gene therapy/gene editing combo could offer hope for some genetic disorders
A hybrid approach that combines elements of gene therapy with gene editing converted an experimental model of a rare genetic disease into a milder form, significantly enhancing survival, shows a multi-institutional study led by the University of Pennsylvania and Children's National Hospital in Washington, D.C.

New technology allows control of gene therapy doses
Scientists at Scripps Research in Jupiter have developed a special molecular switch that could be embedded into gene therapies to allow doctors to control dosing.

Gene therapy: Development of new DNA transporters
Scientists at the Institute of Pharmacy at Martin Luther University Halle-Wittenberg (MLU) have developed new delivery vehicles for future gene therapies.

Gene therapy promotes nerve regeneration
Researchers from the Netherlands Institute for Neuroscience and the Leiden University Medical Center have shown that treatment using gene therapy leads to a faster recovery after nerve damage.

Read More: Gene Therapy News and Gene Therapy Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to